AlzeCure clears key hurdle for drug targeting Alzheimer’s and depression (opens in new tab)

AlzeCure announced on 16 June 2026, that its Phase Ib clinical study of ACD856, the lead candidate in the NeuroRestore platform, completed on schedule with positive results. The trial evaluated safety and tolerability following repeated administration of higher doses than previously studied and measured systemic and central nervous system exposure. According to the company, ACD856 […] The post appeared first on <a href="